|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycaemia in ESRD and was significantly reduced during hyperglycaemia (50 [8-72]%, P=0.03).
|
31608934 |
2020 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma glucagon rose after glucagon delivery (1231±187 vs. 16±1 pg/mL at 30 minutes, p=0.001).No rebound hyperglycemia occurred.
|
31714583 |
2020 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, GIP stimulates glucagon secretion even at hyperglycemia in people with T2D, suggesting that inappropriate GIPR activity in α-cells contributes to the pathogenesis of T2D.
|
31785304 |
2020 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glucagon signaling increases hepatic glucose output, and hyperglucagonemia is partly responsible for the hyperglycemia in diabetes making glucagon an attractive target for therapeutic intervention.
|
31653720 |
2020 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulin and glucagon oppositely modulate blood glucose levels in health, but a combined decline in insulin secretion together with increased glucagon secretion contribute to hyperglycemia in diabetes.
|
31180589 |
2020 |
|
Hyperglycemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glucagon explained up to 86% of the variance in glucagon-like peptide 1, whereas cortisol explained up to 89% of the variance in interleukin 6 in hyperglycemia after AP.
|
31091214 |
2020 |
|
Hyperglycemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After surgery, indices of IS improved, GIP and glucagon levels decreased significantly in both the groups, while there was no significant change in indices of β-cell function in those with hyperglycaemia.
|
30948746 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diabetes is characterized by hyperglycemia due to impaired insulin secretion and aberrant glucagon secretion resulting from changes in pancreatic islet cell function and/or mass.
|
30805033 |
2019 |
|
Hyperglycemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Intestinal SGLT1 inhibition reduces post-prandial hyperglycemia and enhances the increase of plasma glucagon-like peptide-1 (GLP-1) levels.
|
30878385 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although glucagon-like peptide 1- (GLP-1-) based therapy of hyperglycemia in burn injury has shown great potential in clinical trials, its safety is seldom evaluated.
|
30800001 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Knockdown of p52 lowers glucagon-stimulated hyperglycemia, while p52 overexpression augments glucagon response.
|
31541100 |
2019 |
|
Hyperglycemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GLP-1 receptors are involved in the liraglutide-induced relaxation of branched arteries, under normoglycaemic conditions, while GLP-1 inhibition of vascular superoxide levels contributes to GLP-1 receptor-independent potentiation of endothelium-dependent vasodilatation in hyperglycaemia.
|
30403290 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exposure to glucagon-like peptide 1 (GLP1) can ameliorate hyperglycemia in diabetic mice and restore the beta cell mass.
|
31001561 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, the catabolic functions of glucagon, as well as the importance of hepatic redox status for the regulation of glucose production, are emerging as potential targets to reduce hyperglycemia.
|
31494755 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Manipulating the meal sequence of nutrient ingestion may reduce postprandial hyperglycaemia through a direct and GLP-1-mediated stimulation of insulin secretion by plasma AA.
|
30008106 |
2019 |
|
Hyperglycemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on this model, we design infusion rates of either insulin (monotherapy) or insulin and glucagon (dual therapy) that can optimally maintain the blood glucose level within desired limits after consumption of a meal and prevent the onset of both hypoglycemia and hyperglycemia.
|
30893335 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 antagonist significantly blocked the inhibitory effect of IES on hyperglycemia from 15 to 120 min (all p < 0.05).
|
30728346 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is the key defect of hyperglycemia.
|
30099845 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
During pancreatic dysfunction, insulin mediated suppression of glucagon is impaired leading to uncontrolled glucose production by liver and state of hyperglycemia.
|
30713129 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults.
|
30740846 |
2019 |
|
Hyperglycemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, fecal microbiota transplantation (FMT) using fecal material from metformin-treated mice was found to upregulate the expression of GLP-1 and pattern-recognition receptors TLR1 and TLR4 for the improvement in hyperglycemia caused by a high-fat diet.
|
31501716 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Many studies have highlighted the role of dysregulated glucagon secretion in the etiology of hyperglycemia and diabetes.
|
31607563 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In patients with T2D, increased secretion of glucagon (hyperglucagonemia) contributes to diabetic hyperglycemia as proven by the significant lowering of fasting plasma glucose levels following glucagon receptor antagonist administration.
|
30920583 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The GLP1R agonist liraglutide inhibits glucagon; therefore, we hypothesize that the cotreatment of dapagliflozin with liraglutide could reduce hyperglucagonemia and hyperglycemia.
|
31390560 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Post-transplant DM is due to an impaired β-cell function and glucose-induced glucagon suppression during hyperglycemia, which can be reversed by GLP-1R.
|
31261624 |
2019 |